

Zi-Qiang Tang,^{a*} Bo Jiang^b and
Run-Hong Jia^b^aDepartment of Chemistry, Xuzhou Education College, Xuzhou 221006, People's Republic of China, and ^bDepartment of Chemistry, Xuzhou Normal University, Xuzhou 221116, People's Republic of China

Correspondence e-mail: laotu2001@263.net

Key indicators

Single-crystal X-ray study
T = 153 K
Mean $\sigma(\text{C}-\text{C}) = 0.003 \text{ \AA}$
R factor = 0.062
wR factor = 0.124
Data-to-parameter ratio = 13.2For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


5-Cyclopropyl-7,7-dimethyl-10-(4-nitrophenyl)-7,8-dihydro-5H-indeno[1,2-b]quinoline-9,11(6H,10H)-dione

The title compound, $\text{C}_{27}\text{H}_{24}\text{N}_2\text{O}_4$, has been synthesized by the reaction of 4-nitrobenzaldehyde, 3-(cyclopropylamino)-5,5-dimethylcyclohex-2-enone and 1,3-indanedione in a mixed solvent of ethylene glycol and acetic acid under microwave irradiation. The dihydropyridine ring adopts a boat conformation. The molecules are linked by intermolecular $\text{C}-\text{H}\cdots\text{O}$ hydrogen bonds, forming a three-dimensional network structure.

Received 13 October 2006
Accepted 8 November 2006

Comment

1,4-Dihydropyridines (1,4-DHPs) are well known for their pharmacological profiles as calcium channel modulators (Stout & Meyers, 1982). With a 1,4-DHP parent nucleus, indenoquinoline belongs to a class of compounds that are special not only because of their interesting chemical and physical properties, but also because of their immense utility in the pharmaceutical industry. The discovery that indenoquinoline is a potent cytotoxic and antitumor agent has attracted the attention of organic chemists (Yamato *et al.*, 1989; Deady *et al.*, 2000; Chen *et al.*, 2002). It is well established that chemical modifications of the indenoquinoline skeleton may bring remarkable changes in biological activity (Deady *et al.*, 1999). In this paper, we report the crystal structure of such a compound, (I).



In (I), the dihydropyridine ring adopts a boat conformation, with atoms C3 and N1 deviating from the C1/C2/C4/C5 plane by 0.281 (2) and 0.1761 (18) Å, respectively (Fig. 1). The cyclohexene ring adopts a twist-boat conformation: atoms C7 and C8 deviate from the C1/C2/C6/C9 plane by 0.112 (3) and -0.554 (2) Å, respectively. The dihedral angle between the C1/C2/C4/C5 plane and the C17–C22 benzene ring is 73.29 (12)°. The crystal structure is stabilized by intermolecular $\text{C}-\text{H}\cdots\text{O}$ hydrogen bonds (Table 1), resulting in the formation of a three-dimensional network.




Figure 1
The molecular structure of (I), showing the atom-numbering scheme and 30% probability displacement ellipsoids. H atoms have been omitted.




Figure 2
The packing of (I), projected along the *a* axis. Dashed lines indicate hydrogen bonds.

Experimental

The title compound, (I), was prepared by the reaction of 4-nitrobenzaldehyde (1 mmol), 3-(cyclopropylamino)-5,5-dimethylcyclohex-2-enone (1 mmol) and 1,3-indanedione (1 mmol) in a mixed solvent of ethylene glycol (0.5 ml) and acetic acid (1.0 ml) under microwave irradiation for 4 min at 200 W power and 393 K (Emrys Creator microwave oven from Personal Chemistry, Uppsala, Sweden). Upon completion, monitored by thin-layer chromatography, the reaction mixture was cooled to room temperature and then poured into cold water. The solid product was filtered, washed with water and EtOH (95%), and subsequently dried and recryst-

allized from EtOH (95%) to give the pure product. Single crystals of (I) suitable for X-ray diffraction were obtained by slow evaporation of a 95% aqueous ethanol solution (yield 94%; m.p. 541–543 K).

Crystal data

$C_{27}H_{24}N_2O_4$ $Z = 8$
 $M_r = 440.48$ $D_x = 1.349 \text{ Mg m}^{-3}$
 Monoclinic, $C2/c$ Mo $K\alpha$ radiation
 $a = 28.768 (5) \text{ \AA}$ $\mu = 0.09 \text{ mm}^{-1}$
 $b = 8.9966 (12) \text{ \AA}$ $T = 153 (2) \text{ K}$
 $c = 17.703 (3) \text{ \AA}$ Block, red
 $\beta = 108.727 (4)^\circ$ $0.64 \times 0.26 \times 0.15 \text{ mm}$
 $V = 4339.2 (12) \text{ \AA}^3$

Data collection

Bruker SMART CCD area-detector 20588 measured reflections
 diffractometer 3964 independent reflections
 φ and ω scans 3408 reflections with $I > 2\sigma(I)$
 Absorption correction: multi-scan $R_{\text{int}} = 0.043$
 (Jacobson, 1998) $\theta_{\text{max}} = 25.4^\circ$
 $T_{\text{min}} = 0.743$, $T_{\text{max}} = 0.986$

Refinement

Refinement on F^2 $w = 1/[\sigma^2(F_o^2) + (0.038P)^2 + 3.838P]$
 $R[F^2 > 2\sigma(F^2)] = 0.062$ where $P = (F_o^2 + 2F_c^2)/3$
 $wR(F^2) = 0.124$ $(\Delta/\sigma)_{\text{max}} < 0.001$
 $S = 1.20$ $\Delta\rho_{\text{max}} = 0.16 \text{ e \AA}^{-3}$
 3964 reflections $\Delta\rho_{\text{min}} = -0.17 \text{ e \AA}^{-3}$
 301 parameters
 H-atom parameters constrained

Table 1

Hydrogen-bond geometry (\AA , $^\circ$).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$C27-H27B\cdots O4^i$	0.99	2.53	3.496 (3)	164
$C27-H27A\cdots O3^{ii}$	0.99	2.55	3.262 (3)	129
$C12-H12\cdots O2^{iii}$	0.95	2.55	3.298 (3)	136

Symmetry codes: (i) $x, -y + 1, z + \frac{1}{2}$; (ii) $-x + \frac{3}{2}, y - \frac{1}{2}, -z + \frac{1}{2}$; (iii) $-x + 1, -y + 1, -z$.

All H atoms were positioned geometrically and treated as riding, with C–H distances of 0.95–1.00 \AA and with $U_{\text{iso}}(\text{H}) = 1.5U_{\text{eq}}(\text{C})$ for methyl H atoms and $1.2U_{\text{eq}}(\text{C})$ for others.

Data collection: *SMART* (Bruker, 1998); cell refinement: *SAINTE* (Bruker, 1999); data reduction: *SAINTE*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Bruker, 1999); software used to prepare material for publication: *SHELXTL*.

We are grateful for financial support from the National Science Foundation of China (Nos. 20372057 and 20672090), the Natural Science Foundation of the Jiangsu Province (No. BK 2006033) and Graduate Foundation of Xuzhou Normal University (No. 06YI004).

References

- Bruker (1998). *SMART*. Bruker AXS Inc., Madison, Wisconsin, USA.
 Bruker (1999). *SAINTE* and *SHELXTL*. Bruker AXS Inc., Madison, Wisconsin, USA.
 Chen, J. J., Deady, L. W., Kaye, A. J., Finlay, G. J., Baguley, B. C. & Denny, W. A. (2002). *Bioorg. Med. Chem.* **10**, 2381–2386.

- Deady, L. W., Desneves, J., Kaye, A. J., Finlay, G. J., Baguley, B. C. & Denny, W. A. (2000). *Bioorg. Med. Chem.* **8**, 977–984.
- Deady, L. W., Desneves, J., Kaye, A. J., Thompson, M., Finlay, G. J., Baguley, B. C. & Denny, W. A. (1999). *Bioorg. Med. Chem.* **7**, 2801–2809.
- Jacobson, R. (1998). Private communication to the Rigaku Corporation, Tokyo, Japan.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Stout, D. M. & Meyers, A. I. (1982). *Chem. Rev.* **82**, 223–243.
- Yamato, M., Takeuchi, Y., Hashigaki, K., Ikeda, Y., Chang, M. R., Takeuchi, K., Matsushima, M., Tsuruo, T., Tashiro, T., Tsukagoshi, S., Yamashita, Y. & Nakano, H. (1989). *J. Med. Chem.* **32**, 1295–1300.